# US 2010/0305163 A1 · Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305163 A1
- Document ID: US20100305163A1
- Status: Published application
- Kind: A1
- Application number: 12/782,964
- Filed: 2010-05-19
- Published: 2010-12-02
- Earliest claimed: 2009-05-20
- Inventors: Pramod Dattatray Yedurkar; Pramod Kharwade; Narayanan Badri Vishwanathan; Sandeep Mhetre; Vinay Kumar Chiluka; Siva Satya Krishna Babu Pechetti
- Web page: https://patentgrep.com/patent/US20100305163A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the invention relate to pharmaceutical formulations comprising an NSAID and acid reducer drug for therapeutic purposes, and methods of preparing the same. Further aspects of the invention relate to fixed dose pharmaceutical formulations comprising naproxen, or pharmaceutically acceptable salts thereof, and esomeprazole, or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A pharmaceutical fixed unit dosage formulation for oral administration comprising a proton pump inhibitor and a non-steroidal anti-inflammatory drug, wherein at least a portion of non-steroidal anti-inflammatory drug is released when the formulations are immersed into aqueous fluids having pH values below about 3.5.

### Claim 2

A pharmaceutical fixed unit dosage formulation for oral administration comprising a non-steroidal anti-inflammatory drug and a proton pump inhibitor, wherein a portion of a non-steroidal anti-inflammatory drug is released when the formulation is immersed in aqueous media having pH values less than 3.5, and a remaining portion of a non-steroidal anti-inflammatory drug is released when the formulation is immersed in aqueous media having pH values 3.5 or higher.

### Claim 3

A pharmaceutical fixed unit dosage formulation for oral administration comprising a non-steroidal anti-inflammatory drug and a proton pump inhibitor, wherein at least a portion of a non-steroidal anti-inflammatory drug and at least a portion of proton pump inhibitor are released when the formulation is immersed in aqueous media having pH values less than about 3.5.

### Claim 4

A pharmaceutical fixed unit dosage formulation for oral administration comprising a non-steroidal anti-inflammatory drug and a proton pump inhibitor, wherein a portion of a non-steroidal anti-inflammatory drug and at least a portion of proton pump inhibitor are released when the formulation is immersed in aqueous media having pH values less than 3.5, and a remaining portion of a non-steroidal anti-inflammatory drug is released when the formulation is immersed in aqueous media having pH values 3.5 or higher.

### Claim 5 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any of claims 1-4, wherein a non-steroidal anti-inflammatory drug comprises acetylsalicylic acid or naproxen.

### Claim 6 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any of claims 1-4, wherein a proton pump inhibitor comprises omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantaprozole, tanataprazole, or rabeprazole.

### Claim 7 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any of claims 1-4, wherein a non-steroidal anti-inflammatory drug is present in amounts between about 50 mg and about 1500 mg.

### Claim 8 (depends on 1, 2, 3, 4)

The pharmaceutical formulation of any of claims 1-4, wherein a proton pump inhibitor is present in amounts between about 10 mg and about 100 mg.

### Claim 9 (depends on 1, 2, 3, 4)

A method of relieving signs and symptoms of any of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, comprising administering a pharmaceutical formulation of any of claims 1-4.

### Claim 10 (depends on 1, 2, 3, 4)

A method of treating non-steroidal anti-inflammatory drug-associated gastric ulcers, comprising administering a pharmaceutical formulation of any of claims 1-4.
